Testing MVX-220 for Angelman Syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests an experimental medicine called MVX-220 to see if it is safe and effective for people with Angelman Syndrome. It includes both children (ages 4-8) and adults (ages 18-50) who can walk independently and have stable seizure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test showing Angelman Syndrome from a specific gene change (like a deletion or imprinting defect).
- You must be between 4 and 8 years old or between 18 and 50 years old.
- You must be able to walk on your own.
- You must be on steady seizure medicines (no changes in the past month, except weight-based dose adjustments).
- You cannot have certain medical problems, such as liver, kidney, or blood issues, or a history of specific immune or clotting disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called rugonersen for people with Angelman syndrome. The medicine is given as an injection into the fluid around the spinal cord and may help improve symptoms by targeting the genetic cause of the condition.
This study follows people with Angelman syndrome to understand how their symptoms and development change over time. It may help researchers better describe the condition and support future treatments.
This study tests an experimental medicine for Angelman syndrome (AS), a genetic condition affecting the nervous system. The medicine is given by lumbar puncture and aims to improve symptoms.
This study follows people with Angelman syndrome over time to learn more about the condition. It does not test any new treatments, but you need a parent or caregiver to come with you to all visits.
This study follows people with Angelman syndrome over time to learn more about the condition. You can join if you have a confirmed genetic diagnosis and your caregiver agrees to take part.
This trial uses eye tracking to understand how children with Angelman syndrome perceive social cues. Participation helps researchers learn more about social perception for future treatments.
Hear when a new Angelman Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.